Archive \ Volume.14 2023 Issue 1

Features of Digoxin Toxicity in Atrial Fibrillation and Congestive Heart Failure Patients: A Systematic Review

Adyani Md Redzuan, Leon Ya Hui, Shamin Mohd Saffian, Farida Hanim Islahudin, Mohd Makmor Bakry, Siti Azdiah Abdul Aziz
Abstract

Digoxin is a cardiac glycoside indicated for the treatment of congestive heart failure, atrial fibrillation or flutter, and certain cardiac arrhythmias. The use of digoxin is limited due to its narrow therapeutic index nature. In high concentrations, digoxin has been associated with toxicity features such as gastrointestinal symptoms, visual effects, and cardiac arrhythmia. This systematic review aims to summarize cases of digoxin toxicity including the risk factors, possible drug-drug interaction with digoxin, and presenting symptoms. A literature search was conducted through PUBMED and Ovid Medline using the keywords “digoxin” and “toxicity”. The clinical and laboratory manifestations associated with digoxin toxicity were also noted in this review. The search generated 2399 articles and only 10 articles were included in the final analysis. Four out of 10 cases reported diuretics as a possible interacting medication. The symptoms that were usually reported in most cases were nausea and vomiting, change in vision, bradycardia, and increased serum digoxin level. The main risk factors that could lead to digoxin toxicity were females, elderly (60-91 years old), drug-drug interaction; and renal problems (renal disease/ renal impairment/ renal insufficiency). Digoxin toxicity could occur in either low or normal levels of serum digoxin concentration with the presence of concomitant drugs or could be influenced by underlying risk factors. The most common presenting symptoms of digoxin toxicity included nausea and vomiting, change in vision, and bradycardia.


Downloads: 10
Views: 20

How to cite:
Vancouver
Redzuan AM, Hui LY, Saffian SM, Islahudin FH, Bakry MM, Aziz SAA. Features of Digoxin Toxicity in Atrial Fibrillation and Congestive Heart Failure Patients: A Systematic Review. Arch Pharm Pract. 2023;14(1):50-5. https://doi.org/10.51847/qoqV0p1DbK
APA
Redzuan, A. M., Hui, L. Y., Saffian, S. M., Islahudin, F. H., Bakry, M. M., & Aziz, S. A. A. (2023). Features of Digoxin Toxicity in Atrial Fibrillation and Congestive Heart Failure Patients: A Systematic Review. Archives of Pharmacy Practice, 14(1), 50-55. https://doi.org/10.51847/qoqV0p1DbK

Download Citation
References

1.        David MN, Shetty M. Digoxin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2020.

2.        Gheorghiade M, Adams KF Jr, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004;109(24):2959-64.

3.        Tariq S, Aronow WS. Use of Inotropic Agents in Treatment of Systolic Heart Failure. Int J Mol Sci. 2015;16(12):29060-8.

4.        Bauman JL, Didomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs. 2006;6(2):77-86.

5.        Zeng WT, Liu ZH, Li ZY, Zhang M, Cheng YJ. Digoxin Use and Adverse Outcomes in Patients with Atrial Fibrillation. Medicine (Baltimore). 2016;95(12):e2949. 

6.        Al-Khateeb M, Qureshi WT, Odeh R, Ahmed AM, Sakr S, Elshawi R, et al. The impact of digoxin on mortality in patients with chronic systolic heart failure: a propensity-matched cohort study. Int J Cardiol. 2017;228:214-8.

7.        Renard D, Rubli E, Voide N, Borruat FX, Rothuizen LE. Spectrum of digoxin-induced ocular toxicity: a case report and literature review. BMC Res Notes. 2015;8:368.

8.        Kolev KK. Digoxin--'a friend or foe'. BMJ Case Rep. 2012;2012:bcr0120125582. 

9.        Kaneko Y, Nakajima T, Irie T, Kurabayashi M. Ventricular fibrillation following bidirectional tachycardia due to digitalis toxicity. Intern Med. 2011;50(19):2243. 

10.      Vallakati A, Chandra PA, Pednekar M, Frankel R, Shani J. Dronedarone-induced digoxin toxicity: new drug, new interactions. Am J Ther. 2013;20(6):e717-9.

11.      Yang EH, Shah S, Criley JM. Digitalis toxicity: a fading but crucial complication to recognize. Am J Med. 2012;125(4):337-43. 

12.      MacLeod-Glover N, Mink M, Yarema M, Chuang R. Digoxin toxicity: Case for retiring its use in elderly patients? Can Fam Physician. 2016;62(3):223-8. 

13.      Vyas A, Bachani N, Thakur H, Lokhandwala Y. Digitalis toxicity: ECG vignette. Indian Heart J. 2016;68 Suppl 2(Suppl 2):S223-5. 

14.      Naha K, Vivek G, Shetty RK, Shastry BA. Of little yellow men and a fear of the light. BMJ Case Rep. 2013;2013:bcr2013200339. 

15.      Virgadamo S, Charnigo R, Darrat Y, Morales G, Elayi CS. Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World J Cardiol. 2015;7(11):808-16. 

16.      Hu YH, Tai CT, Tsai CF, Huang MW. Improvement of Adequate Digoxin Dosage: An Application of Machine Learning Approach. J Healthc Eng. 2018;2018:3948245. 

17.      Pincus M. Management of digoxin toxicity. Aust Prescr. 2016;39(1):18-20. 

18.      Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;(2):CD003838.

19.      Wang MT, Su CY, Chan AL, Lian PW, Leu HB, Hsu YJ. Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study. Br J Clin Pharmacol. 2010;70(2):258-67.

20.      Marcus FI. Pharmacokinetic interactions between digoxin and other drugs. J Am Coll Cardiol. 1985;5(5 Suppl A):82A-90A. 

21.      That SD. Drug interactions with digoxin: the role of P-glycoprotein. Pharm times. 2004:45.

22.      Kavanagh S, Boparai P. Thyroid dysfunction and drug interactions. Pharm J. 2015;294(7865). doi:10.1211/PJ.2015.20068601

23.      Rehman R, Hai O. Digitalis toxicity. InStatPearls [Internet] 2021 Jul 17. StatPearls Publishing.

24.      Wofford JL, Ettinger WH. Risk factors and manifestations of digoxin toxicity in the elderly. Am J Emerg Med. 1991;9(2 Suppl 1):11-5.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.